Egetis Q3 2024: Financing secured, progress with Emcitate in US and EU - Redeye

Redeye returns with an updated view of Egetis Therapeutics following the Q3 report and recent events in the company. The company has in our view made important progress with Emcitate in the US and EU, and also financed the company in a well-executed directed issue.

Länk till analysen i sin helhet: https://www.redeye.se/research/1054921/egetis-q3-2024-financing-secured-progress-with-emcitate-in-us-and-eu-2?utm_source=finwire&utm_medium=RSS